🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Samvel B. Gasparyan

AstraZeneca (Brazil)

ORCID: 0000-0002-4797-2208

Also affiliated with AstraZeneca (Spain)

MedicineMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF”.

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF

Circulation(2021)10.1161/circulationaha.121.053659

N/A

2.5DataRank · unranked

60 citations

Piotr Ponikowski, Kieran F. Docherty, Samvel B. Gasparyan, Michael Böhm, Chern‐En Chiang +16 more

Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials

The Lancet Diabetes & Endocrinology(2024)10.1016/s2213-8587(24)00219-5

N/A

0DataRank · unranked

11 citations

Peter J. Godolphin, David J. Fisher, Peter Horby, Mikhail Kosiborod, Judith S. Hochman +18 more

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial

Cardiovascular Diabetology(2025)10.1186/s12933-025-02875-6

N/A

0DataRank · unranked

0 citations

Remo H.M. Furtado, Russell Esterline, Jan Oscarsson, Samvel B. Gasparyan, Gary G. Koch +18 more